Which statement about central nervous system (CNS) drug distribution is true?

Which statement about central nervous system (CNS) drug distribution is true?

• A. CNS penetration is often slow and concentrations may not reach therapeutic levels.
• B. If a drug enters the brain, it is rapidly cleared from brain tissue.
• C. All CNS drugs must be highly lipophilic to cross the blood-brain barrier.
• D. The blood-brain barrier is impermeable to all substances.

Answer: (A)

The key idea is that crossing into the CNS is tightly controlled by the blood-brain barrier, so getting a drug to the brain is often slow and brain concentrations may not reach therapeutic levels even when plasma levels look adequate. The barrier consists of tight endothelial junctions and active efflux pumps like P-glycoprotein, which actively push many compounds back into the blood. Because of these features, passage into brain tissue depends on multiple drug properties, not just a simple measure of desirability. Small, non-ionized, moderately lipophilic molecules can diffuse more readily, but many factors still limit entry: molecular size, charge, and whether a drug is a substrate for transporters. Additionally, brain exposure is not always well predicted by simply measuring plasma levels, since CSF concentrations and brain extracellular fluid can equilibrate slowly and are influenced by binding and regional differences in permeability. That’s why the statement about CNS penetration being often slow and potentially subtherapeutic in brain tissue best reflects how distribution to the CNS works in practice. The other ideas don’t fit as well: crossing into the brain isn’t guaranteed to be rapid or guaranteed to yield high and quick brain levels, hence “rapid clearance from brain tissue” isn’t a universal rule. Not all CNS drugs must be highly lipophilic—some rely on specific transporters—and the barrier is not completely impermeable to all substances, since many small or transporter-enabled compounds do enter.

The key idea is that crossing into the CNS is tightly controlled by the blood-brain barrier, so getting a drug to the brain is often slow and brain concentrations may not reach therapeutic levels even when plasma levels look adequate. The barrier consists of tight endothelial junctions and active efflux pumps like P-glycoprotein, which actively push many compounds back into the blood. Because of these features, passage into brain tissue depends on multiple drug properties, not just a simple measure of desirability. Small, non-ionized, moderately lipophilic molecules can diffuse more readily, but many factors still limit entry: molecular size, charge, and whether a drug is a substrate for transporters. Additionally, brain exposure is not always well predicted by simply measuring plasma levels, since CSF concentrations and brain extracellular fluid can equilibrate slowly and are influenced by binding and regional differences in permeability.

That’s why the statement about CNS penetration being often slow and potentially subtherapeutic in brain tissue best reflects how distribution to the CNS works in practice.

The other ideas don’t fit as well: crossing into the brain isn’t guaranteed to be rapid or guaranteed to yield high and quick brain levels, hence “rapid clearance from brain tissue” isn’t a universal rule. Not all CNS drugs must be highly lipophilic—some rely on specific transporters—and the barrier is not completely impermeable to all substances, since many small or transporter-enabled compounds do enter.